Frédéric Bost

12.9k total citations · 2 hit papers
95 papers, 6.7k citations indexed

About

Frédéric Bost is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Frédéric Bost has authored 95 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 24 papers in Cancer Research and 18 papers in Oncology. Recurrent topics in Frédéric Bost's work include Metabolism, Diabetes, and Cancer (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Cancer-related Molecular Pathways (12 papers). Frédéric Bost is often cited by papers focused on Metabolism, Diabetes, and Cancer (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Cancer-related Molecular Pathways (12 papers). Frédéric Bost collaborates with scholars based in France, United States and Monaco. Frédéric Bost's co-authors include Y. Le Marchand‐Brustel, Jean‐François Tanti, Bernard Binétruy, Issam Ben Sahra, Kathiane Laurent, Leslie Caron, Myriam Aouadi, Sophie Giorgetti‐Peraldi, Patrick Auberger and Dan Mercola and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Frédéric Bost

88 papers receiving 6.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

2008 732 citations Issam Ben Sahra, Kathiane Laurent et al. Oncogene profile →
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

2011 526 citations Claire Regazzetti, Guillaume Robert et al. Cancer Research profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Frédéric Bost	4.8k	1.5k	1.5k	989	939	95	6.7k
Elisabetta Mueller	6.1k 1.3×	2.4k 1.6×	1.3k 0.9×	1.4k 1.4×	937 1.0×	51	8.5k
Ramón Bartrons	5.6k 1.2×	3.0k 2.0×	1.2k 0.8×	854 0.9×	914 1.0×	192	8.9k
Cullen M. Taniguchi	2.8k 0.6×	962 0.6×	939 0.6×	1.6k 1.6×	1.2k 1.2×	128	5.9k
Gerald Höefler	4.2k 0.9×	2.3k 1.5×	2.1k 1.4×	2.3k 2.3×	909 1.0×	192	9.3k
Debbie Liao	4.2k 0.9×	1.7k 1.1×	1.4k 1.0×	1.3k 1.3×	858 0.9×	22	6.4k
Sacha Ferdinandusse	5.5k 1.2×	975 0.6×	719 0.5×	1.3k 1.4×	562 0.6×	173	7.5k
Mary Selak	4.4k 0.9×	3.1k 2.1×	703 0.5×	948 1.0×	932 1.0×	55	7.4k
Hideaki Kamata	4.1k 0.9×	1.2k 0.8×	917 0.6×	726 0.7×	967 1.0×	71	6.8k
David B. Shackelford	6.1k 1.3×	1.8k 1.2×	983 0.7×	938 0.9×	2.7k 2.9×	36	8.7k
Michael R. Briggs	4.5k 0.9×	1.1k 0.8×	689 0.5×	1.2k 1.3×	856 0.9×	25	6.4k

Countries citing papers authored by Frédéric Bost

Since Specialization

Citations

This map shows the geographic impact of Frédéric Bost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Bost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Bost more than expected).

Fields of papers citing papers by Frédéric Bost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Bost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Bost. The network helps show where Frédéric Bost may publish in the future.

Co-authorship network of co-authors of Frédéric Bost

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Bost. A scholar is included among the top collaborators of Frédéric Bost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Bost. Frédéric Bost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fontaine‐Vive, Fabien, et al.. (2025). Development of a reliable, sensitive, and convenient assay for the discovery of new eIF5A hypusination inhibitors. PLoS ONE. 20(2). e0308049–e0308049.

Bost, Frédéric, et al.. (2025). Prostate cancer and pollution: Dangerous connections. Annales d Endocrinologie. 86(3). 101769–101769.

Contenti, Julie, Yongjian Guo, Magalie Larcher, et al.. (2024). HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma. Cell Death Discovery. 10(1). 338–338. 2 indexed citations

Guo, Yingbo, et al.. (2024). YAP1 modulation of primary cilia‐mediated ciliogenesis in 2D and 3D prostate cancer models. FEBS Letters. 598(24). 3071–3086.

Belaïd, Amine, et al.. (2024). Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS‐010759. Molecular Oncology. 18(7). 1719–1738. 23 indexed citations

Muller, Claire, Jérôme Kluza, William Laine, et al.. (2024). The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors. Cancer Cell International. 24(1). 132–132. 2 indexed citations

Luka, Marine, Natascha Pigat, E. Navarro, et al.. (2023). Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy. American Journal Of Pathology. 194(1). 30–51. 3 indexed citations

Borchiellini, Delphine, Aline Guillot, Jean-Baptiste Paoli, et al.. (2021). TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(6). 501–509. 34 indexed citations

Jaune, Emilie, Cyril Ronco, Patricia Abbe, et al.. (2021). Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. Cell Death and Disease. 12(1). 19 indexed citations

10.

Contenti, Julie, Maeva Dufies, Julien Parola, et al.. (2020). Co‐culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia. Journal of Cellular and Molecular Medicine. 24(5). 2931–2941. 7 indexed citations

11.

Torrino, Stéphanie, Maeva Dufies, Zied Djabari, et al.. (2019). PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness. Cancer Research. 79(13). 3268–3280. 29 indexed citations

12.

Muller, Claire, François Foulquier, Marine Houdou, et al.. (2018). Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells. Breast Cancer Research and Treatment. 171(3). 581–591. 31 indexed citations

13.

Dirat, Béatrice, Isabelle Ader, Muriel Golzio, et al.. (2014). Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells. Molecular Cancer Therapeutics. 14(2). 586–596. 34 indexed citations

14.

Regazzetti, Claire, Guillaume Robert, Kathiane Laurent, et al.. (2011). Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. Cancer Research. 71(13). 4366–4372. 526 indexed citations breakdown →

15.

Sahra, Issam Ben, Kathiane Laurent, Sandy Giuliano, et al.. (2010). Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells. Cancer Research. 70(6). 2465–2475. 434 indexed citations

16.

Marchand‐Brustel, Y. Le, Philippe Gual, Myriam Aouadi, et al.. (2006). Obésité, Diabète et insulinorésistance. Altérations du message insulinique. Journal de la Société de Biologie. 200(1). 93–97.

17.

Caron, Leslie, Frédéric Bost, Matthieu Prot, Paul Hofman, & Bernard Binétruy. (2005). A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells. Oncogene. 24(41). 6281–6291. 34 indexed citations

18.

Bost, Frédéric, Leslie Caron, Emmanuel Vial, et al.. (2001). The defective transforming phenotype of c-Jun Ala63/73 is rescued by mutation of the C-terminal phosphorylation site. Oncogene. 20(50). 7425–7429. 5 indexed citations

19.

Bost, Frédéric, Maryam Mehrpour, & Jean‐Pierre Martin. (1998). Inter‐α‐trypsin inhibitor proteoglycan family. European Journal of Biochemistry. 252(3). 339–346. 188 indexed citations

20.

Péoc’h, Michel, Dominique Pasquier, Frédéric Bost, et al.. (1994). [Histiocytosis of the pelvic lymph node and hip prosthesis].. PubMed. 14(4). 263–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact